Skip to main content
Premium Trial:

Request an Annual Quote

MedStar, Indivumed Enter Biobank Collaboration

NEW YORK (GenomeWeb) – MedStar Health said today that it has made a deal with German firm Indivumed, making it a contributor to the company's biobank and giving it access to the data therein.

According to MedStar, the partnership gives its researchers access to biospecimens and associated clinical data in Indivumed's global cancer database, which may help uncover new individualized diagnosis and treatment strategies for cancer.

Under what it called a "multi-year agreement," MedStar researchers will in turn collect lung, breast, colorectal, pancreatic and other cancer tissues from the health system's most active cancer programs, which they will then contribute according to Indivumed's biobanking standards.

Tissue collection at Georgetown Lombardi will continue pursuant to Georgetown University's existing agreement with Indivumed, the company said.

Additional terms of the deal were not disclosed.

"By participating in the Indivumed global network, we'll have access to a critical mass of biological samples and clinical data for use in unique research for our community," Neil Weissman, president of the MedStar Health Research Institute, said in a statement.

Indivumed has signed a number of similar access and contribution agreements with other health systems and research groups recently, including Northwell Health, The University of Rochester Medical Center, and the Geisinger Health System.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.